0 versus 2.0 days, p < 0.001; odds ratio 3.65, 95% CI 1.97- 6.75). Significant differences were noted for type of hospital intra/inter transfer category prior to EDIMCU admission (p < 0.001); however, only ICU transfer
(patients that were discharged from ICU and admitted in the EDIMCU) appeared as possible risk AP24534 concentration factor for delirium (63.6% Delirium versus 36.4% No Delirium) (Table (Table1).1). Regarding clinical status, cardiovascular, pulmonary, gastrointestinal, Inhibitors,research,lifescience,medical and haemato-oncologic were the most common reasons for admission to the EDIMCU; occurrence rates of delirium were significantly different between groups (p < 0.033), but only patients with neurologic-related diagnosis appeared more likely to develop delirium (equal percentage between those with Delirium versus No Delirium) (Table (Table11). Table 2 Delirium status classified by delirium subtype Biochemical parameters For the analyzed biochemical parameters (see Additional file 3) at Inhibitors,research,lifescience,medical EDIMCU admission, when compared with No Delirium patients, Delirium patients had higher blood Inhibitors,research,lifescience,medical urea (mean 86.1 mg/dL versus 58.2 mg/dL, p < 0.001) and creatinine (mean 1.99 mg/dL versus
1.55 mg/dL, p < 0.006) at admission and lower hemoglobin concentration (mean 10.6 g/dL versus 11.3 g/dL, p < 0.038) (Table (Table3).3). Osmolarity and hemoglobin have a Pearson correlation value of 0.285 (p < 0.001). At discharge, delirium patients remained with significantly Inhibitors,research,lifescience,medical higher blood urea levels (mean 84.6 mg/dL versus 54.5 mg/dL, p < 0.006) and significantly lower hemoglobin concentrations (mean 10.0 g/dL versus 10.8 g/dL, p < 0.03) compared with No Delirium patients (Table (Table3).3). Osmolarity, a more accurate measure of (de)hydration than blood urea or sodium Inhibitors,research,lifescience,medical levels alone , was calculated from sodium, glucose and blood urea nitrogen levels at admission and was significantly different between groups (mean 320.55 mOsm/L versus 308.55 mOsm/L, p = 0.001). Table 3 Biochemical parameters stratified
by delirium status One-month outcomes and multivariate analysis At the 1-month outcome analysis 51 patients (17.1%) were excluded (patients Dichloromethane dehalogenase with no contact and/or clinical information at 1-month after discharge); a total of 50 patients from the Delirium group and 188 from No Delirium group were evaluated (Figure (Figure11 and Table Table4).4). In the Delirium group mortality at the 1-month evaluation was 30% (combined death in the EDICUM and death after discharge; respectively, n = 7 and n = 8 for each setting) versus 10% for the No Delirium group (combined death in the EDICUM and death after discharge; respectively, n = 3 and n = 16) (p < 0.001). Furthermore, 26% patients were institutionalized versus 16.5% of the No Delirium group (p = 0.022). The estimated odds ratio for a poor outcome at 1-month associated with delirium status was 3.51 (CI 1.842 – 6.698).